Why ODF Projects Need “Equipment Power” to Scale from Lab to GMP
Share
Many oral dissolvable film (ODF) projects succeed in the laboratory stage, but struggle when transitioning to GMP-scale production. Issues such as unstable films, inconsistent content, drying failures, and sudden drops in yield are common. One root cause is the technology gap between lab-scale and production-scale equipment. To achieve a smooth R&D-to-GMP transition, strong “equipment power” is needed to bridge the gap.
Common “R&D Disconnection” Problems
- Lab coating methods differ from production-scale machines, making parameters invalid
- Drying, tension control, and liquid supply systems are not aligned with actual production
- Lack of in-line detection systems, leading to non-traceable and non-auditable data
- Lab environments often fail to meet GMP cleanliness standards, limiting regulatory support
How Equipment Supports the Lab-to-GMP Transition
- Adopt pilot equipment such as MJ150-L, designed with the same principles as GMP machines, to validate scale-up processes in advance
- Equip systems with in-line thickness measurement, automatic tension control, and closed liquid supply for consistent data
- Enable data collection and export functions to meet audit trail requirements
- Record complete process parameters to support registration and export filing
Recommended Equipment:
HUANGHAI’s Lab-to-GMP Solutions
HUANGHAI offers a complete equipment ecosystem covering R&D, pilot, and commercial GMP stages:
- Lab-scale: MJ100 small coating lab system (optional)
- Pilot-scale: MJ150-L, enabling reproducible parameter migration for scale-up
- Commercial GMP: MJ150 with output up to 20,000 strips/hour, fully GMP-compliant
- Seamless integration with testing instruments, enabling a “manufacturing + testing” traceability loop
Conclusion
Success in ODF projects is not only about formulation — it is about process control and equipment alignment. Deploying pharmacopeia-grade pilot equipment and scale-up strategies early is the key to efficient market entry and successful regulatory approval.
*Features Huanghai's exclusive patented hot-air drying technology (Patent No. CN201668734U) ensuring uniform bottom-up heating.
Frequently Asked Questions
Q: What is the difference between an ODF film and a transdermal patch?
A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.
Q: What production output can I expect from a Huanghai ODF machine?
A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.
Q: What drying technology does Huanghai use for ODF production?
A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.
Q: What are the GMP requirements for ODF production equipment?
A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.
Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?
A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.
Explore Complete ODF & TDDS Manufacturing Solutions
Huanghai offers end-to-end ODF film production lines — from lab-scale R&D (BY-300A / MJ150-L) to commercial manufacturing (MJ150). GMP-certified and 21 CFR Part 11 compliant.
Equipment Certifications & Regulatory Compliance
All Huanghai pharmaceutical instruments hold ISO 9001, CE, and relevant GMP certifications. ODF production line equipment is fully 21 CFR Part 11 compliant.